1. Home
  2. CYCC vs GIFT Comparison

CYCC vs GIFT Comparison

Compare CYCC & GIFT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CYCC
  • GIFT
  • Stock Information
  • Founded
  • CYCC 1992
  • GIFT 1999
  • Country
  • CYCC Malaysia
  • GIFT United States
  • Employees
  • CYCC N/A
  • GIFT N/A
  • Industry
  • CYCC Biotechnology: Pharmaceutical Preparations
  • GIFT Catalog/Specialty Distribution
  • Sector
  • CYCC Health Care
  • GIFT Consumer Discretionary
  • Exchange
  • CYCC Nasdaq
  • GIFT Nasdaq
  • Market Cap
  • CYCC 47.6M
  • GIFT 53.3M
  • IPO Year
  • CYCC N/A
  • GIFT N/A
  • Fundamental
  • Price
  • CYCC $0.35
  • GIFT $1.73
  • Analyst Decision
  • CYCC Strong Buy
  • GIFT Strong Buy
  • Analyst Count
  • CYCC 1
  • GIFT 1
  • Target Price
  • CYCC $11.00
  • GIFT $4.00
  • AVG Volume (30 Days)
  • CYCC 7.1M
  • GIFT 29.1K
  • Earning Date
  • CYCC 05-13-2025
  • GIFT 05-19-2025
  • Dividend Yield
  • CYCC 43.71%
  • GIFT N/A
  • EPS Growth
  • CYCC N/A
  • GIFT N/A
  • EPS
  • CYCC N/A
  • GIFT N/A
  • Revenue
  • CYCC $43,000.00
  • GIFT $88,934,036.00
  • Revenue This Year
  • CYCC $137.21
  • GIFT $26.85
  • Revenue Next Year
  • CYCC N/A
  • GIFT N/A
  • P/E Ratio
  • CYCC N/A
  • GIFT N/A
  • Revenue Growth
  • CYCC N/A
  • GIFT 2.05
  • 52 Week Low
  • CYCC $0.17
  • GIFT $0.50
  • 52 Week High
  • CYCC $4.00
  • GIFT $4.27
  • Technical
  • Relative Strength Index (RSI)
  • CYCC 65.97
  • GIFT N/A
  • Support Level
  • CYCC $0.23
  • GIFT N/A
  • Resistance Level
  • CYCC $0.30
  • GIFT N/A
  • Average True Range (ATR)
  • CYCC 0.06
  • GIFT 0.00
  • MACD
  • CYCC 0.01
  • GIFT 0.00
  • Stochastic Oscillator
  • CYCC 68.57
  • GIFT 0.00

About CYCC Cyclacel Pharmaceuticals Inc.

Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib and plogosertib.

About GIFT RDE Inc. Common Stock

Giftify Inc through its wholly-owned subsidiary, has been in the business of connecting digital consumers, businesses and communities with dining and merchant deal options throughout the United States. The company connects digital consumers, businesses, and communities offering dining and merchant deal options nationwide restaurants, and retailers to customers. The Company buys merchant gift cards from the general public and distributors at a discount and then resells them at a markup.

Share on Social Networks: